Wow - at last the Priority Review announcement is here.
This "represents an important milestone for company" - SI didn't waste too many words.
But, this is darn important!
It bring legitimacy to Mesoblast and kills off all the "if and buts" about the science.
Now it is all there for us to see: a paradigm shift in medical treatment and our company charging towards commercialisation
Bring it on!
GLTASHs
Ann: FDA Accepts BLA for RYONCIL and Agrees to Priority Review, page-11
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.020(2.12%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 92.0¢ | $2.103M | 2.270M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 106422 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 59027 | 3 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |